Loading
OI
OptiNose, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Clavelli Victor M, was filed 24 May 2021.
OptiNose, Inc.: what insiders have been doing
This page follows insider dealings at OptiNose, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. No insider at OptiNose, Inc. has published a filing in the past twelve months. The most recent one dates from 21 May 2025.
The full history, which starts in 2021, counts 2 purchases against 30 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
90
Thresholds
n/a
Buy Volume
€109,729
2 ops. · all time
Sell Volume
€466,487
30 ops. · all time
Who traded when
BuySaleMichael F. Marino III3 sales
Ramy A. Mahmoud3 sales
Paul Spence Jr.1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$67.4M
Gross profitUS$4.7M7% margin
Net income-US$18.5M-27.5% margin
Last declaration on 21 May 2025
Declarations90 total
125,204 sharesCommon StockSEC:0001104659-25-051350:0
102,813 sharesCommon StockSEC:0001104659-25-051345:0
30,541 sharesCommon StockSEC:0001104659-25-051349:0
303,176 sharesCommon StockSEC:0001104659-25-051340:0
246 shares@ US$5.611.4% of flowCommon StockSEC:0001494650-25-000040:0
368 shares@ US$5.610.8% of flowCommon StockSEC:0001494650-25-000038:0
1,223 shares@ US$5.29100.0% of flowCommon StockSEC:0001494650-25-000028:0
2,145 shares@ US$5.2911.8% of flowCommon StockSEC:0001494650-25-000026:0
6,376 shares@ US$5.2913.4% of flowCommon StockSEC:0001494650-25-000024:0
21,150 shares0Common StockSEC:0001494650-25-000009:0
53,475 shares0Common StockSEC:0001494650-25-000013:0
13,875 shares0Common StockSEC:0001494650-25-000011:0
17,025 shares0Common StockSEC:0001494650-25-000007:0
3,050 shares@ US$0.441.4% of flowCommon StockSEC:0001494650-24-000172:0
4,614 shares@ US$0.440.8% of flowCommon StockSEC:0001494650-24-000170:0
150,000 shares0Common StockSEC:0001494650-24-000145:0
4,881 shares@ US$0.871.6% of flowCommon StockSEC:0001494650-24-000130:0
3,226 shares@ US$0.872.7% of flowCommon StockSEC:0001494650-24-000132:0
111,426 shares@ US$1.1448.4% of flowCommon StockSEC:0001494650-24-000110:0
49,408 shares@ US$1.1455.9% of flowCommon StockSEC:0001494650-24-000112:0
6,845 shares@ US$1.1460.1% of flowCommon StockSEC:0001494650-24-000114:0
624 shares@ US$1.195.8% of flowCommon StockSEC:0001494650-24-000099:0
2,946 shares@ US$1.193.5% of flowCommon StockSEC:0001494650-24-000097:0
3,817 shares0Common StockSEC:0001494650-24-000095:0
6,113 shares0Common StockSEC:0001494650-24-000093:0
25 of 90 declarations
About OptiNose, Inc.
OptiNose, Inc. is a U.S.-based specialty pharmaceutical company that built its business around patients treated by ENT and allergy specialists. Incorporated in Delaware in May 2010, the company developed around a proprietary drug-delivery platform, the Exhalation Delivery System (EDS), designed to deliver therapies into the nasal cavity in a way that supports local treatment. OptiNose’s principal operating base has been in Yardley, Pennsylvania, with an additional facility in Ewing, New Jersey. Its common shares were listed on the Nasdaq Global Select Market under the ticker OPTN prior to the completion of the announced transaction with Paratek Pharmaceuticals. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1494650/000149465018000025/R9.htm?utm_source=openai))
The company’s core commercial asset was XHANCE (fluticasone propionate), a steroid nasal spray delivered through the EDS platform. XHANCE received FDA approval in September 2017 for nasal polyps and became broadly available through U.S. commercial channels in April 2018. In January 2023, the label wording was updated to align with current FDA terminology for chronic rhinosinusitis with nasal polyps. In practical terms, XHANCE was the company’s main revenue engine and the key driver of OptiNose’s valuation, making the business highly concentrated but also highly visible within a focused ENT niche. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1494650/000149465024000018/optn-20231231.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, OptiNose occupied a specialized position in chronic rhinosinusitis and related ENT indications. Its differentiation came less from scale and more from its delivery technology and the clinical utility of its flagship product. The company competed against larger pharmaceutical and specialty pharmaceutical groups, as well as other treatment options used by physicians in practice. That said, the model also carried clear risks typical of single-product biopharma companies: product concentration, dependence on reimbursement and physician adoption, financing needs, and sensitivity to debt covenant constraints. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1494650/000149465025000064/optn-20241231.htm?utm_source=openai))
The most important recent development was the March 19, 2025 merger agreement under which Paratek Pharmaceuticals agreed to acquire OptiNose and its approved product XHANCE. SEC filings and company communications indicate consideration of $9.00 per share in cash plus potential contingent value rights linked to U.S. XHANCE sales milestones. OptiNose also reported fourth-quarter and full-year 2024 results showing XHANCE net revenue of $22.4 million for Q4 2024 and $78.2 million for full-year 2024. For investors, OptiNose is best viewed as a U.S. Nasdaq-listed specialty pharma asset that transitioned from standalone commercialization toward sector consolidation through a strategic acquisition. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1494650/000149465025000047/ex-991pressrelease.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
